TRGFT-201 is under clinical development by Orca Biosystems and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRGFT-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TRGFT-201 overview

TRGFT-201 is under development for the treatment of myelodysplastic syndrome, B-cell acute lymphoblastic leukemia, acute myeloid leukemia, acute lymphoid leukemia, hematopoietic stem cell transplant, myelofibrosis, blastic plasmacytoid dendritic cell neoplasm (Natural killer cell lymphomas), chronic myelocytic leukemia. It comprises of purified donor-derived regulatory T-cell (Treg) plus CD34 and hematopoietic progenitor cells. It is administered through intravenous route.

It was also under development for other unspecified indications.

Orca Biosystems overview

Orca Biosystems (Orca Bio) is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. The company is headquartered in Menlo Park, California, the US.

For a complete picture of TRGFT-201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.